Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.
Four dengue virus serotypes (DENV1-4) circulate globally, causing more human illness than any other arthropod-borne virus. Dengue can present as a range of clinical manifestations from undifferentiated fever to Dengue Fever to severe, life-threatening syndromes. However, most DENV infections are inapparent. Yet, little is known about determinants of inapparent versus symptomatic DENV infection outcome. Here, we analyzed over 2,000 DENV infections from 2004 to 2011 in a prospective pediatric cohort study in Managua, Nicaragua. Symptomatic cases were captured at the study health center, and paired healthy annual samples were examined on a yearly basis using serological methods to identify inapparent DENV infections. Overall, inapparent and symptomatic DENV infections were equally distributed by sex. The mean age of infection was 1.2 years higher for symptomatic DENV infections as compared to inapparent infections. Although inapparent versus symptomatic outcome did not differ by infection number (first, second or third/post-second DENV infections), substantial variation in the proportion of symptomatic DENV infections among all DENV infections was observed across study years. In participants with repeat DENV infections, the time interval between a first inapparent DENV infection and a second inapparent infection was significantly shorter than the interval between a first inapparent and a second symptomatic infection. This difference was not observed in subsequent infections. This result was confirmed using two different serological techniques that measure total anti-DENV antibodies and serotype-specific neutralizing antibodies, respectively. Taken together, these findings show that, in this study, age, study year and time interval between consecutive DENV infections influence inapparent versus symptomatic infection outcome, while sex and infection number had no significant effect. Moreover, these results suggest that the window of cross-protection induced by a first infection with DENV against a second symptomatic infection is approximately 2 years. These findings are important for modeling dengue epidemics and development of vaccines.
Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Magelda
M
Montoya
Lionel
L
Gresh
Juan Carlos
JC
Mercado
Katherine L
KL
Williams
Maria José
MJ
Vargas
Gamaliel
G
Gutierrez
Guillermina
G
Kuan
Aubree
A
Gordon
Angel
A
Balmaseda
Eva
E
Harris
D000293:Adolescent; D000367:Age Factors; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003715:Dengue / Q000453:epidemiology* / Q000276:immunology / Q000473:pathology* / Q000821:virology; D003716:Dengue Virus / Q000145:classification / Q000276:immunology / Q000302:isolation & purification*; D005260:Female; D006801:Humans; D008297:Male; D009527:Nicaragua / Q000453:epidemiology; D011446:Prospective Studies; D012008:Recurrence; D012703:Serotyping; D013997:Time Factors
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral